RxDoctor Payments Data

Gene Zdenek, MD

Ophthalmology · Reseda, CANPI 1326104514

Payments from drug & device makers

$3,831in general payments, 2019–2025

Across 127 payments — averaging $30.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$996
  • Sun Pharmaceutical Industries Inc.$386
  • Aerie Pharmaceuticals, Inc.$366
  • Oyster Point Pharma, Inc.$279
  • AbbVie$261
  • Harrow Eye, LLC$225
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$3,71097%
  • Gifts$191%
  • Entertainment$1023%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,831 in reported general payments places this provider in the 70th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$456,580
Medicare patients
321
Services billed
5,367

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MieboPerfluorohexyloctane/Pf42$30,529
VyzultaLatanoprostene Bunod74$30,229
LumiganBimatoprost63$23,244
XiidraLifitegrast25$22,327
ZyletTobramycin/Lotepred Etab25$8,614
CombiganBrimonidine Tartrate/Timolol15$3,590
Lotemax SmLoteprednol Etabonate14$3,367
Tobradex StTobramycin/Dexamethasone12$2,789
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha14$124
Latanoprost21$65

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Miebo, Vyzulta, Xiidra$996$83,085141 claims
AbbVieLumigan, Combigan$261$26,83478 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCZylet, Lotemax Sm$182$11,98139 claims
Eyevance Pharmaceuticals LLCTobradex St$21$2,78912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Reseda

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →